<DOC>
	<DOCNO>NCT01651663</DOCNO>
	<brief_summary>The purpose study determine whether Arbidol ( Umifenovir ) effective treatment Prophylaxis Influenza Common Cold</brief_summary>
	<brief_title>A Study Arbidol ( Umifenovir ) Treatment Prophylaxis Influenza Common Cold</brief_title>
	<detailed_description>Influenza virus infection result major health economic burden worldwide . The World Health Organization estimate average global burden interpandemic influenza approximately 1 billion case influenza , 3 5 million case severe illness , 300 000 500 000 death annually . Arbidol ( Umifenovir ) currently license treatment prevention influenza Russian Federation . Arbidol ( Umifenovir ) direct antiviral effect . Arbidol ( Umifenovir ) belong fusion inhibitor ; interacts virus hemagglutinin thus prevents fusion viral envelope cell membrane . The aim study obtain additional data safety therapeutic efficacy investigational product Arbidol ( Umifenovir ) patient diagnosis influenza common cold . Furthermore , study viral resistance patient seasonal influenza infection treat Arbidol ( Umifenovir ) perform .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Common Cold</mesh_term>
	<criteria>Signed Patient Information Informed Consent Form . Male female patient 18 65 year . Outpatients uncomplicated* form common cold influenza . Illness duration 36 hour . At least one episode body temperature 38Â°C high past 36 hour . Presence least one follow symptom : Headache , fatigue/malaise , pain/aches muscle , fever/chills . Patient 's ability adequately cooperate . A history allergic reaction investigational drug Arbidol ( Umifenovir ) hypersensitivity drug . Illness duration 36 hour . Any complication influenza/common cold sign severe progressive disease* moment selection participation study . A history influenza vaccination carry last 12 month . Evidence severe hematological , immunological , pulmonary , urogenital , gastrointestinal , hepatic , renal , endocrine , metabolic , psychiatric , dermatovenereological disease , collagenoses , nutritional disorder , know patient 's history , physical examination laboratory test , may limit patient participate study may affect result study . Participation clinical study past 4 month . Common cold infection last 4 week enrollment . Administration Arbidol ( Umifenovir ) last 4 week onset disease . Administration immunomodulators , interferon inducer , homeopathic , hormonal , antiviral antibacterial drug last 4 week selection participation study . Alcohol substance abuse . Hospitalization moment selection participation study . Pregnant lactate woman . Any associated disease condition , opinion investigator , might restrict impede patient 's participation study affect study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Influenza</keyword>
</DOC>